One of the most distressing symptoms of Parkinson's disease is the psychosis which causes people to have hallucinations and delusions. It is a quite common condition which affects about 40 percent of all patients with Parkinson's disease. And the number of Parkinson's patients is growing rapidly along with the increase of the elderly population.
There is no FDA approved drug for Parkinson's psychosis.
Acadia Pharmaceuticals' (NASDAQ:ACAD) promising new drug, Pimavanserin is expected to be submitted for approval at the end of 2014 and possibly begin producing revenue from 2015.
Acadia, located in San Diego, California, is a small company with less than 50 employees.
Pimavanserin is special because it does not cause serious side effects like other...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|